Fig 1.
Of 655 home health patients assessed for eligibility, 412 did not meet the inclusion criteria and 133 patients either declined to participate, refused home health, already enrolled or the clinician would not order pharmacogenetic testing. Of 110 randomly allocated patients, 53 patients in arm 1 were assigned to not receive intervention and 57 patients from arm 2 were assigned to received pharmacogenetic intervention. CYP, cytochrome; DDI, drug-drug interaction; DGI, drug-gene Interaction; DDGI, drug-drug-gene interaction; ED, emergency department; ESRD, end stage renal disease; N, number of patients.
Table 1.
Demographic characteristics of patients.
Table 2.
The number of patients by the number of events for each primary outcome, by the treatment group.
Table 3.
Comparison of primary and exploratory outcomes between the treatment groups.
Table 4.
Comparison of the time-to-event outcomes between the untested and tested groups.
Fig 2.
Cumulative rate (%) for re-hospitalizations, ED visits, and composite events using Kaplan-Meier estimator.
2A and 2B represent the Kaplan-Meier curves for the time to first re-hospitalization and to the first ED visits, respectively. 2C and 2D represent the Kaplan-Meier curves for the time-to-cumulative composite event outcomes for re-hospitalizations + ED visits and re-hospitalizations + ED visits + deaths, respectively. ED, emergency department; p, p value. The vertical lines on the survival curves show the times when event-free subjects reach the end of their protocol pre-specified follow-up of approximately 60 days (55–65 days).
Table 5.
Distribution of evaluated cytochrome P-450 (CYP) metabolic phenotypes between the Home Health Trial and another published study population [1,6].
Table 6.
Comparison of YouScript® recommendation severity of drug-drug, drug-gene, and drug-drug-gene interaction between the Home Health Trial and another published study population [16].